Doubling Its Bet In IPF, Gilead Buys Arresto Biosciences For $225 Million

Deal also calls for sales-based milestones, likely pegged to antibody currently in Phase I in idiopathic pulmonary fibrosis and advanced solid tumors.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet